Inhibition of platelet aggregation with intravenous and oral administration of carboprostacyclin in man.
Intravenous infusion of carboprostacyclin, a chemically stable analogue of prostacyclin (PGI2) resulted in ex-vivo inhibition of ADP-induced platelet aggregation at doses that did not produce significant changes in blood pressure or heart rate. Oral administration of relatively large doses of this compound also inhibited ex-vivo ADP-induced platelet aggregation but this was accompanied by headache, facial flush, tachycardia and changes in blood pressure.
D000244:Adenosine Diphosphate / Q000037:antagonists & inhibitors / Q000494:pharmacology; D000284:Administration, Oral; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D003864:Depression, Chemical; D004305:Dose-Response Relationship, Drug; D011464:Epoprostenol / Q000008:administration & dosage / Q000494:pharmacology* / Q000031:analogs & derivatives; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects*; D011453:Prostaglandins / Q000494:pharmacology*; D013997:Time Factors
D011453:Prostaglandins; D000244:Adenosine Diphosphate; C026678:carboprostacyclin; D011464:Epoprostenol